Pegasus Partners Ltd. Eli Lilly & CO Transaction History

Pegasus Partners Ltd.

$991 Million
Q2 2024

A detailed history of Pegasus Partners Ltd. transactions in Eli Lilly & CO stock. As of the latest transaction made, Pegasus Partners Ltd. holds 1,403 shares of LLY stock, worth $1.24 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

1,403

Previous 1,199 17.01%

Holding current value

$1.24 Million

Previous $932,000 36.27%

% of portfolio

0.13%

Previous 0.1%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$724.87 - $909.04 $147,873 - $185,444	204 Added 17.01%	1,403 $1.27 Million
Q1 2024 Apr 24, 2024	BUY	$592.2 - $792.28 $6,514 - $8,715	11 Added 0.93%	1,199 $932,000
Q4 2023 Feb 12, 2024	SELL	$525.19 - $619.13 $29,410 - $34,671	-56 Reduced 4.5%	1,188 $692,000
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $4,781 - $6,592	11 Added 0.89%	1,244 $668,000
Q2 2023 Aug 04, 2023	SELL	$350.74 - $468.98 $30,865 - $41,270	-88 Reduced 6.66%	1,233 $578,000
Q1 2023 May 10, 2023	BUY	$310.63 - $364.82 $27,335 - $32,104	88 Added 7.14%	1,321 $453,000
Q3 2022 Nov 10, 2022	SELL	$296.48 - $337.87 $5,929 - $6,757	-20 Reduced 1.6%	1,233 $399,000
Q2 2022 Aug 12, 2022	BUY	$278.73 - $327.27 $5,574 - $6,545	20 Added 1.62%	1,253 $406,000
Q1 2022 May 13, 2022	SELL	$234.69 - $291.66 $41,540 - $51,623	-177 Reduced 12.55%	1,233 $353,000
Q4 2021 Feb 09, 2022	BUY	$224.85 - $279.04 $317,038 - $393,446	1,410 New	1,410 $389,000
Q1 2018 May 09, 2018	SELL	$74.21 - $87.6 $1.05 Million - $1.24 Million	-14,174 Closed	0 $0
Q4 2017 Feb 08, 2018	SELL	$81.94 - $87.89 $478,529 - $513,277	-5,840 Reduced 29.18%	14,174 $1.2 Million
Q3 2017 Nov 09, 2017	BUY	$77.07 - $85.54 $1.54 Million - $1.71 Million	20,014	20,014 $1.71 Million

Others Institutions Holding LLY

# of Institutions

3,870

Shares Held

751M

Call Options Held

6.34M

Put Options Held

7.97M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $843B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pegasus Partners Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Pegasus Partners Ltd. with notifications on news.

Account

Pegasus Partners Ltd. Eli Lilly & CO Transaction History